Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:27:44.974Z.
Calculation as of: 2026-10-06T20:27:44.974Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 651b3973db42e019715e3a8a4e975a06fcddd3d3dc4e12dda44c0d1ac22a80ea
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$18.65M
EV/EBITDA Ratio
N/A
TTM Avg
466.09x
3Y Avg
466.09x
5Y Avg
466.09x
Market Cap
$18.30M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$22.00M
EV/EBITDA Ratio
N/A
TTM Avg
6.88x
3Y Avg
5.95x
5Y Avg
5.95x
Market Cap
$17.39M
EV/EBITDA Ratio
N/A
TTM Avg
47.55x
3Y Avg
64.91x
5Y Avg
64.91x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $19.77M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $20.53M | N/A | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | N/A | 466.09x | 466.09x | 466.09x |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A | 6.88x | 5.95x | 5.95x |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A | 47.55x | 64.91x | 64.91x |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A | 19.19x | 19.19x | 19.19x |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
